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Abstract
Angiosarcoma is an aggressive malignancy that arises spontaneously or secondarily to ionising
radiation or chronic lymphoedema1. Previous work has identified aberrant angiogenesis, including
occasional somatic mutations in angiogenesis signalling genes, as a key driver of angiosarcoma1.
Here, we employed whole genome, exome, and targeted sequencing to study the somatic changes
underpinning primary and secondary angiosarcoma. We identified recurrent mutations in two
genes, PTPRB and PLCG1, which are intimately linked to angiogenesis. The endothelial
phosphatase PTPRB, a negative regulator of vascular growth factor tyrosine kinases, harboured
predominantly truncating mutations in 10/39 (26%) tumours. PLCG1, a signal transducer of
tyrosine kinases, presented with a recurrent, likely activating R707Q missense variant in 3/34
cases (9%). Overall, 15/39 (38%) tumours harboured at least one driver mutation in angiogenesis
signalling genes. Our findings inform and reinforce current therapeutic efforts to target
angiogenesis signalling in angiosarcoma.
We performed whole genome sequencing of three angiosarcomas, along with paired normal
DNA from the same patients. The somatic mutation burden of the three cases varied from
0.7–2.2 substitutions per megabase and 0.1–0.2 indels per megabase (Supplementary Fig. 1;
Supplementary Table 1-5). Remarkably, in two of the three angiosarcomas we identified
truncating mutations in the PTPRB (VE-PTP) gene, a tyrosine phosphatase specific to
vascular endothelium that inhibits angiogenesis2. One tumour had a nonsense substitution
(p.E1444*) and the other both a nonsense (p.C1693*) and a missense (p.Y309C) mutation.
To explore this observation further, we extended our investigation to 36 angiosarcomas
which we studied by whole exome sequencing (n=8) or by targeted sequencing of 360
cancer genes (n=4; Supplementary Table 6) or 28 angiogenesis-related genes (n=24;
Supplementary Table 7). The entire footprint of PTPRB was sequenced, to enable the
identification of structural rearrangements in addition to coding point mutations.
Angiogenesis-related genes were also sequenced in eight epithelioid
haemangioendotheliomas, nine Kaposi’s sarcomas, and two haemangiomas.
In total, we identified 14 PTPRB mutations in 10/39 (26%) angiosarcomas, comprising eight
nonsense, two essential splice, a frameshift insertion and three missense variants (Fig. 1). No
large deletions or rearrangements were identified, although the presence of small intragenic
deletions cannot be excluded. All truncating mutations disrupt the coding sequence of
PTPRB before or within the tyrosine phosphatase domain. Two of the missense mutations
(Y309C and W130R) lie within the extracellular domain of PTPRB, inhibition of which has
been shown to disrupt PTPRB function3. The third missense mutation, P1996L, lies within
the tyrosine phosphatase domain. The in silico variant effect prediction tool, SIFT, ascribes
deleterious consequences to these missense variants. No PTPRB mutations were identified
in haemangioendothelioma, Kaposi sarcoma, or in haemangioma. Inactivating PTPRB
mutations are also rare in other cancer types, as documented in COSMIC4, suggesting that
PTPRB disruption is largely specific to angiosarcoma. Statistical analysis demonstrated that
these truncating PTPRB mutations were extremely unlikely to have accumulated by chance
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in angisoarcoma (q = 10−9), suggesting that inactivating PTPRB mutations are driver events.
Notably, all PTPRB mutations were identified in tumours that were either known to be
secondary and / or have MYC amplification, a biomarker of radiation-associated secondary
angiosarcoma5 (p = 0.005). In this group the prevalence of PTPRB mutations was 45%
(10/22 cases).
Four angiosarcomas harboured two different non-synonymous PTPRB mutations each,
including at least one truncating variant in each case. In two of these cases both mutations
were truncating, consistent with biallelic inactivation, suggesting that PTPRB operates as a
recessive cancer gene. In six angiosarcomas there was a single heterozygous PTPRB variant,
5 truncating and one missense, without evidence of LOH. The presence of a single
detectable non-synonymous mutation in 60% of tumours is not unusual for tumour
suppressor genes (Supplementary Fig. 2). We analysed published catalogues of somatic
mutation from 4,073 tumours to determine the frequency of a second mutation, including
LOH, co-occurring with a truncating mutation in established suppressor genes. This analysis
indicates that the pattern of mutation we observed in PTPRB is compatible with a recessive
driver mechanism (Supplementary Fig. 2). Nevertheless, we cannot exclude the possibility
that other mechanisms such as haploinsufficiency or dominant negative effects are
operative.
PTPRB, a negative regulator of angiogenesis, is expressed exclusively in vascular
endothelium, both during development and in adult tissues2,6. It inhibits VEGFR2, VE-
cadherin, and angiopoietin signalling, thus acting as an integral modifier of
angiogenesis2,3,6-15. In in vitro models of angiogenesis, PTPRB inhibition increases
angiogenesis12. PTPRB null mice die in utero and display severe vascular malformations6.
Although the role of PTPRB as a negative regulator of angiogenesis is well established, it is
not known whether PTPRB driven angiogenesis can be inhibited through pharmacological
VEGF inhibition. Consequently, we investigated the effects of knockdown of PTPRB on
primary cultures of human umbilical vein endothelial cells (HUVEC). Silencing of PTPRB
via siRNA induced features of angiogenesis such as spheroid sprouting after 24 hours and
spindle-like morphology. In the presence of sunitinib or vatalinib, inhibitors of VEGFR2
kinase, these features were abolished (Figure 2; Supplementary Figure 3). These findings in
HUVEC, a model of vascular endothelium, provide a rationale for exploring whether
PTPRB mutation status correlates with treatment response to anti-angiogenic agents.
To explore the contribution of other genes in angiosarcoma we analysed variant data from
15 angiosarcomas interrogated by whole genome, exome, or cancer gene sequencing (Fig.
3). Cancer genes mutated in more than one tumour included TP53 (3/15 cases; 20%),
KDM6A (2/15 cases; 13%), and MYC (6/15 cases; 40%). Strikingly, we also identified a
recurrent missense variant, R707Q, in PLCG1, in 3/15 cases (20%). PLCG1 encodes
phospholipase C gamma 1 (PLCγ1), a tyrosine kinase signal transducer within the
phosphoinositide signalling pathway. Statistical analysis showed that the enrichment of
R707Q mutation in angiosarcoma is highly significant (q = 0.000002). Capillary sequencing
of an additional 15 cases of angiosarcoma indicated that the overall prevalence of R707Q
mutations was 9% (3/34 cases). No PLCG1 mutations were found in any of the other tumour
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types investigated here. Notably, all three PLCG1 R707Q mutations co-occurred with
PTPRB mutations.
The presence of a single recurrent R707Q missense variant suggests that PLCG1 is activated
in angiosarcoma. Arginine 707 lies within the auto-inhibitory cSH2 domain of PLCγ116-19
and provides structural support to this domain. In silico modelling of the mutated protein
predicts that the substituted glutamine destabilises the cSH2 domain which may result in
overactive PLCγ1 (Supplementary Fig. 4). Disruption of the auto-inhibitory cSH2 domain
has been shown to cause murine and human immune disorders through constitutive
activation of PLCγ enzymes16-19. Interestingly, forward genetic screening of zebrafish has
identified PLCG1 as a non-redundant regulator of arterial angiogenesis that transduces
activation of VEGF signalling20,21, and Plcg1-deficient mice exhibit reduced
vasculogenesis22. PLCG1 is ubiquitously expressed in normal tissue17,19, and whole RNA
sequencing of four angiosarcomas, including two positive for PLCG1 R707Q, demonstrated
PLCG1 expression in each case. In the context of existing knowledge about PLCG1, our
observations therefore lend support to the hypothesis that activated PLCG1 drives
angiosarcoma, downstream of receptor tyrosine kinases, through constitutive activation of
angiogenesis signalling. The effects of PLCG1 mutations on the response to therapeutics
targeting tyrosine kinases will be an important future investigation.
In addition to 15 angiosarcomas screened for driver mutations, we performed a focused
screen for mutations in angiogenesis-related genes (Supplementary Table 6) in a further 24
angiosarcomas. Considering both cohorts together, 15/39 angiosarcomas harbour at least one
mutation in an angiogenesis-related gene highlighting aberrant angiogenesis as a common
driver in a subset of tumours. Mutated genes included H/K/N-RAS (5/39 cases), PIK3CA
(1/39 cases), and FLT4 (1/39 cases). We did not find variants in VEGFR2 (KDR) that have
previously been reported23 (Supplementary Table 1). Amongst other vascular tumours we
identified one Kaposi sarcoma (n=9) with a PIK3CA and one epithelioid
haemangioendothelioma (n=8) with a PTEN driver mutation (Supplementary Table 1).
Interestingly, in our series aberrant angiogenesis was most frequent amongst secondary
and/or MYC-amplified angiosarcomas (12/22 cases), although this observation requires
investigation in larger series. There was no evidence of mutual exclusivity of mutations in
angiogenesis-related genes (Fig. 3; Supplementary Table 1). In four angiosarcomas we
found more than one angiogenesis-related gene mutated, indicating that targeting treatment
exclusively at the tyrosine kinase level may not suffice to overcome aberrant angiogenesis.
As angiosarcoma is a rare tumour, combined efforts to curate larger patient series are
required to explore further the somatic changes that underpin its pathogenesis. This study,
however, provides a first comprehensive insight into the somatic variation in angiosarcoma
and identifies frequent mutations in angiogenesis-related genes in a subset of tumours. The
next challenge will be to functionally explore these findings in appropriate angiosarcoma
models that accommodate the complexity of the driver landscape we report here. It is now
indicated to determine the clinical utility of PTPRB and PLCG1 as possible biomarkers of
secondary disease and as novel therapeutic targets in angiosarcoma.
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Online methods
Patient samples
Informed consent was obtained from all subjects and ethical approval obtained from
Cambridgeshire 2 Research Ethics Service (reference 09/H0308/165). Collection and use of
patient samples were approved by the appropriate institutional review board (IRB) of each
institution.
Whole genome, exome and cancer gene sequencing
DNA was extracted from 11 angiosarcomas as well as matched normal tissue derived from
the same individuals. Three cases were whole genome sequenced to an average depth of at
least 40× or 30× for tumour and normal DNA, respectively, as previously described24.
Whole exome sequencing was performed on 8 cases as previously described25, and at least
70% of the coding sequence was covered by 30×. DNA extracted from an additional 4
tumours that did not have matched normal tissue DNA were subjected to targeted
sequencing of 360 established and putative cancer gene using a custom made bait set
(Agilent) for target enrichment (Supplementary Table 7). Paired end sequencing was
performed on Illumina Hiseq 2000 or 2500 analysers. Reads were aligned to the reference
human genome (NCBI37) by using BWA on default settings26. Reads which were
unmapped or PCR-derived duplicates were excluded from the analysis.
Variant detection
The CaVEMan (cancer variants through expectation maximization) algorithm was used to
call single nucleotide substitutions25. To call insertions and deletions, we used split-read
mapping implemented as a modification of the Pindel algorithm27. To call rearrangements
we applied the BRASS (breakpoint via assembly) algorithm, which identifies
rearrangements by grouping discordant read pairs that point to the same breakpoint event25.
Post-processing filters were applied to the output to improve specificity. Mutations were
annotated to Ensembl version 58.
Variant validation
In whole genome samples, all coding variants as well as randomly selected mutations, in
total 508/15292 (3.3%) substitutions and 342/1386 (25%) indels, were experimentally
validated by whole exome sequencing or targeted capture with massively parallel
sequencing25. The overall precision of the catalogue of substitutions and indels was thus
determined to be at least 94%. Rearrangements were validated by defining the exact location
of the breakpoint at nucleotide resolution through extraction of split reads across the
breakpoint, algorithmically or previously25. Variants called in whole exome samples were
confirmed by visual inspection or resequencing.
Angiogenesis gene screen
43 tumours were included in this screen: 24 angiosarcomas; 9 Kaposi’s sarcomas; 8
haemangioendotheliomas; 2 haemangiomas. Genes of interest (Supplementary Table 6) and
genotyping SNPs were enriched through targeted capture and sequenced by massively
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parallel sequencing, as described before25. The PLCG1 R707Q mutation was screened for
by capillary sequencing (primer sequences available on request).
RNA sequencing and analysis
Total RNA was isolated from fresh frozen tissue of 4 angiosarcomas using trizol. Standard
Illumina RNA libraries of poly-A selected RNA were sequenced on an Illumina HiSeq 2000
(paired end, 75 base pair read length). TopHat28 (version 1.3.3) was used for alignment.
Expression values were derived using Cufflinks29 (version 1.0.2).
Detection of copy number variation
Copy number data were derived from whole genome or exome reads using the ASCAT
algorithm (version 2.2) and validated by SNP6.0 in 2 cases30. In the whole exome extension
study, amplifications were derived by comparing the coverage in candidate genes against
average coverage across the exome, after normalization using matched germline exome
sequencing data. A 1.75-fold increase (corresponding to >= 5 copies in 50% tumour cells)
was reported as an amplification. In the targeted extension study, amplifications were
derived by comparing the coverage in candidate genes against the coverage in 96 SNPs of
the same sample, both normalised against data from a panel of non-tumour samples. A
fivefold increase in relative, normalised coverage in tumours was reported as an
amplification. To assess LOH in PTPRB, all SNPs that lie within the footprint of the gene
were interrogated and their allele fraction assessed for deviations from 0.5.
Cell culture
Human Umbilical Vein Endothelial Cells (HUVEC) pooled from multiple donors were
purchased from Lonza (Wokingham, UK). These were routinely cultured in Endothelial
Growth Medium 2 (EGM-2) (Lonza) up to passage 7 and cultured in Endothelial Basal
Medium 2 (EBM-2) (Lonza) during the experiments.
RNAi transfection
Stealth siRNAs targeting PTPRB (HSS108847 and HSS108849) and the Stealth RNAi™
siRNA Negative Control Med GC Duplex #2 were purchased from Life Technologies.
siRNA was transfected into HUVEC at a final concentration of 30nM using Lipofectamine
RNAiMAX reagent (Life Technologies). Cells were transfected at 50% confluency in Opti-
MEM reduced Serum Medium with GlutamMAX 1 (Life Technologies) and used after 24
hours.
Western blotting and staining
Antibodies for western blotting were obtained from the following suppliers; anti-b-actin
HRP (Sigma), anti-VEGFR2 and anti-P-VEGFR2 (Cell Signalling). Staining was performed
on formalin fixed cells using anti-VE-cadherin (Cell Signalling) and Alexa Fluor 488 (Life
Technologies).
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Hanging drop assay
HUVEC were trypsinised and resuspended in EBM2 (Lonza) containing 2% foetal calf
serum (FCS) at a concentration of 2.5×104 cells/ml. Methylcellulose was added at 0.25%
(w/v) and 20μl drops were seeded in non-adherent dish. After inversion of the plate,
suspended cells form a single spheroid containing approximately 500 cells. Treated
spheroids were incubated with 1μM Sunitinib (Cell Signaling Technology, Inc) or 100nM
Vatalanib (Santa Cruz) for 1hr prior to being embedded in a fibrin gel using 2.5mg/ml
fibrinogen-PBS solution (Sigma) and 0.007 units of thrombin (Sigma). Once clotting
occurred, EBM-2 containing 2% FCS was added with or without 1μM Sunitinib or 100nM
Vatalanib. Spheroid photographs were taken after 24 hours using an AMG Evos XL Core
digital microscope (Fisher Scientific, Loughborough, UK). Sprouting area was measured
using ImageJ64 software and the results were analysed using Graphad Prism version 6
(Graphpad Software).
Statistical analyses
A Fisher’s exact test was used to assess the significance of the association between PTPRB
mutations and subtypes of angiosarcoma.
For analysis of in vitro findings, a one-way ANOVA was performed on the data with a
Sidak’s multiple comparisons test.
To determine whether the frequency of individual mutations classes was higher than
expected by chance for each gene, we implemented a likelihood model as previously
described31. To determine the probability of the identical PLCG1 mutations having occurred
by chance, we used the following approach: Using the rates of each mutation class estimated
using the aforementioned method, the neutral rate of such an event assuming uniform
mutation rates was determined to be 5.905e-06. The probability of seeing this site mutated
three times in the coding sequence of 11 samples that were interrogated by unbiased
sequencing was therefore approximately 4.57e-14 (cumulative Poisson distribution).
Adjusting the p-value for the total number of sites in the exome the q-value for this mutation
is 1.49e-06.
In order to analyse the frequency of two-hits in known tumour suppressor genes we
downloaded publicly available catalogues of somatic mutations including copy number data
from 4,073 tumours of the Tumour Cancer Gene Atlas consortium (as of November 2013).
For every gene of a list of established tumour suppressors (see Supplementary Figure 2) we
selected all those samples in which the gene had a truncating mutation (nonsense, essential
splice site or out-of-frame indels) and quantified the frequency of a second mutations, i.e.
truncating, loss of heterozygosity, missense, or in-frame indel, in the gene. Error bars in
Supplementary Figure 2 indicate the 95% confidence intervals of the total fraction of 2-hit
samples (using a Chi-square approximation, as implemented in the function “prop.test” in R
version 3.0.1).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Distribution of mutations in PTPRB.
Each circle / square / triangle represents a mutation. Red: truncating mutations. Blue:
missense.
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Figure 2.
Sensitivity of PTPRB-driven angiogenesis to VEGF inhibition.
A) HUVEC spheroids embedded in a fibrin gel were photographed after 24 hours of
treatment (×10 magnification). B) Quantification of spheroid sprouting area. Error bars
represent 1 × standard deviation. *p<0.0001.
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Figure 3.
Driver variants in angiosarcoma
Likely driver variants are indicated by coloured rectangles. Truncating variants (red) include
nonsense, essential splice and frameshift indels. Missense substitutions are indicated in blue,
amplifications in green and rearrangements in orange. Secondary angiosarcomas are either
clinically classified as secondary or unclassified cases with MYC amplification.
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